Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX).
Leblond P, Tresch-Bruneel E, Probst A, Néant N, Solas C, Sterin A, Boulanger T, Aerts I, Faure-Conter C, Bertozzi AI, Chastagner P, Entz-Werlé N, De Carli E, Deley ML, Bouche G, André N. Leblond P, et al. Among authors: tresch bruneel e. Cancers (Basel). 2023 Mar 28;15(7):2020. doi: 10.3390/cancers15072020. Cancers (Basel). 2023. PMID: 37046681 Free PMC article.
Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma.
Hamimed M, Gattacceca F, André N, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, Leblond P. Hamimed M, et al. Among authors: tresch bruneel e. Br J Clin Pharmacol. 2022 May;88(5):2096-2117. doi: 10.1111/bcp.15131. Epub 2021 Dec 13. Br J Clin Pharmacol. 2022. PMID: 34709655 Free article. Clinical Trial.
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.
Hamimed M, Leblond P, Dumont A, Gattacceca F, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, André N, Ciccolini J. Hamimed M, et al. Among authors: tresch bruneel e. Cancer Chemother Pharmacol. 2022 Jul;90(1):29-44. doi: 10.1007/s00280-022-04446-y. Epub 2022 Jun 25. Cancer Chemother Pharmacol. 2022. PMID: 35751658 Clinical Trial.
Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial.
Kotecki N, Le Cesne A, Tresch-Bruneel E, Ray-Coquard I, Chevreau C, Bertucci F, Bogart E, Mir O, Pautier P, Decoupigny E, Clisant S, Blay JY, Penel N. Kotecki N, et al. Among authors: tresch bruneel e. Am J Clin Oncol. 2018 Nov;41(11):1094-1100. doi: 10.1097/COC.0000000000000430. Am J Clin Oncol. 2018. PMID: 29509592
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A, Blay JY, Domont J, Tresch-Bruneel E, Chevreau C, Bertucci F, Delcambre C, Saada-Bouzid E, Piperno-Neumann S, Bay JO, Mir O, Ray-Coquard I, Ryckewaert T, Valentin T, Isambert N, Italiano A, Clisant S, Penel N. Le Cesne A, et al. Lancet Oncol. 2015 Mar;16(3):312-9. doi: 10.1016/S1470-2045(15)70031-8. Epub 2015 Feb 11. Lancet Oncol. 2015. PMID: 25680558 Clinical Trial.
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Lebellec L, Bertucci F, Tresch-Bruneel E, Bompas E, Toiron Y, Camoin L, Mir O, Laurence V, Clisant S, Decoupigny E, Blay JY, Goncalves A, Penel N. Lebellec L, et al. Oncotarget. 2016 Nov 8;7(45):73984-73994. doi: 10.18632/oncotarget.12172. Oncotarget. 2016. PMID: 27659533 Free PMC article.
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Bompas E, Le Cesne A, Tresch-Bruneel E, Lebellec L, Laurence V, Collard O, Saada-Bouzid E, Isambert N, Blay JY, Amela EY, Salas S, Chevreau C, Bertucci F, Italiano A, Clisant S, Penel N. Bompas E, et al. Ann Oncol. 2015 Oct;26(10):2168-73. doi: 10.1093/annonc/mdv300. Epub 2015 Jul 22. Ann Oncol. 2015. PMID: 26202596 Free PMC article. Clinical Trial.
How to report toxicity associated with targeted therapies?
Cabarrou B, Boher JM, Bogart E, Tresch-Bruneel E, Penel N, Ravaud A, Escudier B, Mahier Ait-Oukhatar C, Delord JP, Roché H, Filleron T. Cabarrou B, et al. Ann Oncol. 2016 Aug;27(8):1633-8. doi: 10.1093/annonc/mdw218. Epub 2016 May 23. Ann Oncol. 2016. PMID: 27217543 Free article.
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
Lebellec L, Bertucci F, Tresch-Bruneel E, Ray-Coquard I, Le Cesne A, Bompas E, Blay JY, Italiano A, Mir O, Ryckewaert T, Toiron Y, Camoin L, Goncalves A, Penel N, Le Deley MC. Lebellec L, et al. Among authors: tresch bruneel e. BMC Cancer. 2018 Oct 11;18(1):963. doi: 10.1186/s12885-018-4828-1. BMC Cancer. 2018. PMID: 30305054 Free PMC article. Clinical Trial.
19 results